Search

Displaying results 2701 - 2710 of 8196 in total
  1. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    There has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine. … With this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  2. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.

  3. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do

  4. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors
  5. Drug

    Quinupramine

    go.drugbank.com/drugs/DB13246
    Approved

    Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant [A175003].

  6. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Targeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes. … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.

  7. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

    Synonyms: Fosfato de adenosina, Ado5'P
  8. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    [L32649,L32664] In March 2021, several EU member countries halted the administration of AstraZeneca's COVID-19 Vaccine due to signals of an increased risk of blood clots associated with thrombocytopenia … [L32674] A phase I/II single-blinded, randomized, placebo-controlled trial to investigate the safety, efficacy, and immunogenicity of the vaccine began in April 2020 with an expected completion date

  9. Drug

    Tocainide

    go.drugbank.com/drugs/DB01056
    ApprovedWithdrawn

    An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  10. Drug

    Imidurea

    go.drugbank.com/drugs/DB14075
    Approved

    Imidurea is an antimicrobial preservative used in cosmetics. It acts as a formaldehyde releaser.